당뇨병을 동반하지 않는 심부전 환자에서 SGLT2 Inhibitor의 심장기능에 대한 효과 (Evaluation of Cardiac Function Outcomes in Non-Diabetic Heart Failure Patients Treated with SGLT2 Inhibitors)

서지정보

· 발행기관 : 한국병원약사회
· 수록지 정보 : 병원약사회지 / 41권 / 3호 / 225 ~ 236페이지
· 저자명 : 이하늘, 이해원, 금민정, 고종희, 김수현, 손은선, 유윤미

초록

Background : Extensive clinical studies have demonstrated that irrespective of diabetes status, sodium glucose co-transporter 2 inhibitors (SGLT2i) effectively reduce heart failure-related hospitalizations, and are advantageous in enhancing cardiac function. However, limited domestic studies have focused on the effects of SGLT2i in non-diabetic heart failure (HF) patients. Therefore, this study aims to investigate the cardiac function effects of SGLT2i in Korean HF patients without diabetes.
Methods : This retrospective study analyzed electronic medical records from January 2021 to December 2022. We focused on adult HF patients without diabetes who started SGLT2i therapy at Tertiary Hospital. The evaluation of cardiac function improvement involved comparing echocardiographic parameters before the initiation of SGLT2i therapy, and at intervals ranging (3 to 12) months post-therapy.
Results : This study comprised 128 patients, divided into two groups based on left ventricular ejection fraction (LVEF) and SGLT2i type. The median duration of follow-up was 189 days. Following treatment with SGLT2i, significant reductions were observed in left ventricular end-diastolic dimension (−2.7 mm; p<0.01), left ventricular end-systolic dimension (−3.3 mm; p<0.01), left ventricular mass index (−11.5 g/m2; p<0.01), and left atrium volume index (−4.5 mL/m2; p<0.01). Furthermore, significant improvement in LVEF was observed, showing an increase of 3.9% (p<0.01). The enhancement of cardiac function following SGLT2 inhibitor treatment was notably more significant in patients with LVEF ≤ 40%.
Conclusion : The findings of this study demonstrate that in Korean non-diabetic HF patients, SGLT2i led to significant improvements in cardiac function, as evidenced by echocardiographic parameter alterations. Notably, these improvements were more pronounced in patients with reduced ejection fraction. Additionally, the study found no significant difference in cardiac function outcomes between empagliflozin and dapagliflozin treatments. This suggests that SGLT2i may offer a viable therapeutic option for managing HF with reduced ejection fraction in non-diabetic patients.

영어초록

Background : Extensive clinical studies have demonstrated that irrespective of diabetes status, sodium glucose co-transporter 2 inhibitors (SGLT2i) effectively reduce heart failure-related hospitalizations, and are advantageous in enhancing cardiac function. However, limited domestic studies have focused on the effects of SGLT2i in non-diabetic heart failure (HF) patients. Therefore, this study aims to investigate the cardiac function effects of SGLT2i in Korean HF patients without diabetes.
Methods : This retrospective study analyzed electronic medical records from January 2021 to December 2022. We focused on adult HF patients without diabetes who started SGLT2i therapy at Tertiary Hospital. The evaluation of cardiac function improvement involved comparing echocardiographic parameters before the initiation of SGLT2i therapy, and at intervals ranging (3 to 12) months post-therapy.
Results : This study comprised 128 patients, divided into two groups based on left ventricular ejection fraction (LVEF) and SGLT2i type. The median duration of follow-up was 189 days. Following treatment with SGLT2i, significant reductions were observed in left ventricular end-diastolic dimension (−2.7 mm; p<0.01), left ventricular end-systolic dimension (−3.3 mm; p<0.01), left ventricular mass index (−11.5 g/m2; p<0.01), and left atrium volume index (−4.5 mL/m2; p<0.01). Furthermore, significant improvement in LVEF was observed, showing an increase of 3.9% (p<0.01). The enhancement of cardiac function following SGLT2 inhibitor treatment was notably more significant in patients with LVEF ≤ 40%.
Conclusion : The findings of this study demonstrate that in Korean non-diabetic HF patients, SGLT2i led to significant improvements in cardiac function, as evidenced by echocardiographic parameter alterations. Notably, these improvements were more pronounced in patients with reduced ejection fraction. Additionally, the study found no significant difference in cardiac function outcomes between empagliflozin and dapagliflozin treatments. This suggests that SGLT2i may offer a viable therapeutic option for managing HF with reduced ejection fraction in non-diabetic patients.

참고자료

· 없음